Sexual Mixing and HIV Transmission Potential Among Greek Men Who have Sex with Men: Results from SOPHOCLES.

HIV incidence among men who have sex with men (MSM) in Greece remains unchanged despite effective response to a recent outbreak among people who inject drugs (PWID). Network factors are increasingly understood to drive transmission in epidemics. The primary objective of the study was to characterize MSM in Greece, their sexual behaviors, and sexual network mixing patterns. We investigated the relationship between serostatus, sexual behaviors, and self-reported sex networks in a sample of MSM in Athens, Greece, generated using respondent driven sampling. We estimated mixing coefficients (r) based on survey-generated egonets. Additionally, multiple logistic regression was used to estimate adjusted odds ratios (AOR) and to assess relationships between serostatus, sexual behaviors, and sociodemographic indicators. A sample of 1,520 MSM participants included study respondents (n = 308) and their network members (n = 1,212). Mixing based on serostatus (r = 0.12, σr = 0.09-0.15) and condomless sex (r = 0.11, σr = 0.07-0.14) was random. However, mixing based on sex-drug use was highly assortative (r = 0.37, σr = 0.32-0.42). This study represents the first analysis of Greek MSM sexual networks. Our findings highlight protective behavior in two distinct network typologies. The first typology mixed assortatively based on serostatus and sex-drug use and was less likely to engage in condomless sex. The second typology mixed randomly based on condomless sex but was less likely to engage in sex-drug use. These findings support the potential benefit of HIV prevention program scale-up for this population including but not limited to PrEP.

Prevalence of 25-hydroxyvitamin D deficiency in an urban general internal medicine academic practice.

Vitamin D deficiency has received increased academic interest because of its association with many common disease processes. The goal of our study was to document the prevalence of vitamin D deficiency. A retrospective chart review of 25-hydroxyvitamin D (ng/mL) levels at the University of Tennessee Health Science Center was conducted on general internal medicine patients over an 18-month period. The 25-hydroxyvitamin D deficient patients were divided into four groups: severe (<7 ng/mL), moderate (7.0-20.9 ng/mL), mild (21-31.9 ng/mL), and sufficient (>32 ng/mL). We found that an overwhelming majority of our patients were mildly to severely deficient (87 percent) with 17 percent severely deficient, 53 percent moderately deficient, 17 percent mildly deficient, and only 13 percent sufficient. The prevalence of 25-hydroxyvitamin D deficiency among this population was higher than expected based on the prevalence of 25-hydroxyvitamin D deficiency reported in literature. Based on this data, we believe a greater percentage of the general population needs to be studied in order to discover the true prevalence of vitamin D deficiency.

Prevalence of 25-hydroxyvitamin D deficiency in an urban general internal medicine academic practice.

Vitamin D deficiency has received increased academic interest because of its association with many common disease processes. The goal of our study was to document the prevalence of vitamin D deficiency. A retrospective chart review of 25-hydroxyvitamin D (ng/ml) levels at the University of Tennessee Health Science Center was conducted on general internal medicine patients over an 18-month period. The 25-hydroxyvitamin D deficient patients were divided into four groups: severe (<7 ng/ml), moderate (7.0-20.9 ng/ml), mild (21-31.9 ng/ml), and sufficient (>32 ng/ml). We found that an overwhelming majority of our patients were mildly to severely deficient (87 percent) with 17 percent severely deficient, 53 percent moderately deficient, 17 percent mildly deficient, and only 13 percent sufficient. The prevalence of 25-hydroxyvitamin D deficiency among this population was higher than expected based on the prevalence of 25-hydroxyvitamin D deficiency reported in literature. Based on this data, we believe a greater percentage of the general population needs to be studied in order to discover the true prevalence of vitamin D deficiency.

Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.

OBJECTIVES: The dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are effective modulators of fasting and postprandial hyperglycemia in patients with type 2 diabetes mellitus (T2DM). In 2013 the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) clinical trial found an increased risk of heart failure exacerbation, as a secondary outcome, among patients treated with saxagliptin. This study examines the safety of DPP-4 inhibitors as a class in T2DM in relation to risk of heart failure exacerbations. METHODS: Retrospective cohort study of two groups of patients using data from the national Department of Veteran's Affairs (VA) Health Care System: patients initially prescribed DPP-4 inhibitors with or without second-generation sulfonylureas and/or metformin (exposed group) compared with patients initially prescribed only second-generation sulfonylureas and/or metformin (unexposed group) between August 1, 2013, and August 30, 2016. The primary aim of this study was to determine the difference in 1-year heart failure exacerbation rate in patients with T2DM between the exposed and unexposed groups. Data were analyzed using the χ2 Student t test and Kaplan-Meier analysis. Significance was set at p<0.05. RESULTS: The study evaluated 672,265 patients: 33,614 patients in the exposed group and 638,651 patients in the unexposed group. Overall, 130 (0.38%) heart failure exacerbations were documented in the exposed group, and 2222 (0.34%) heart failure exacerbations were documented in the unexposed group; the difference in exacerbation rate was nonsignificant between groups (p=0.24). In a subgroup analysis of patients with a baseline diagnosis of heart failure, the difference in rate of heart failure exacerbations remained nonsignificant (p=0.334). CONCLUSIONS: Patients in the veteran population with T2DM treated with DPP-4 inhibitors did not demonstrate a significant increase in risk for heart failure exacerbation, regardless of whether a patient had been previously diagnosed with heart failure. This finding potentially supports safe usage of DPP-4 inhibitors in this patient population regardless of heart failure diagnosis.